FOLFOX, FOLFIRI, or FOLFOXIRI chemotherapy with bevacizumab (BV) are considered standard 1st line treatment options for patients with metastatic colorectal cancer (mCRC). We developed and validated a molecular signature predictive of efficacy of oxaliplatin-based chemotherapy combined with BV in patients with mCRC.
Clinical validation of a machine-learning derived signature predictive of outcomes from first-line oxaliplatin-based chemotherapy in advanced colorectal cancer
Cremolini, Chiara;Antoniotti, Carlotta;Falcone, Alfredo;
2020-01-01
Abstract
FOLFOX, FOLFIRI, or FOLFOXIRI chemotherapy with bevacizumab (BV) are considered standard 1st line treatment options for patients with metastatic colorectal cancer (mCRC). We developed and validated a molecular signature predictive of efficacy of oxaliplatin-based chemotherapy combined with BV in patients with mCRC.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
